N-[(1R)-2,3-Dihydro-1H-inden-1-yl]-adenosine is a synthetic adenosine derivative characterized by the presence of a chiral (R)-2,3-dihydro-1H-inden-1-yl group attached to the N6-position of the adenine base. This structural modification imparts specific pharmacological properties distinct from the parent nucleoside. This compound is primarily recognized as a potent and selective agonist for the adenosine A1 receptor (A1AR). Its high affinity and selectivity for the A1AR subtype make it a valuable pharmacological tool in neuroscience and cardiovascular research for studying adenosine-mediated signaling pathways, which are involved in processes such as neuroprotection, cardiac function, and sleep regulation. Beyond its role as a classical receptor agonist, derivatives and analogs of such adenosine ligands have been explored in modern drug discovery platforms, including their potential utility as targeting ligands (warheads) in the design of Proteolysis Targeting Chimeras (PROTACs) aimed at degrading disease-relevant proteins. The (R)-N-(2,3-dihydro-1H-indenyl) moiety is a key structural feature that contributes to its receptor binding profile and metabolic stability. As a research chemical, it is handled under standard laboratory safety protocols for bioactive compounds.